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Abstract Vitamin K prophylaxis is recommended to
prevent the hazard of haemorrhage caused by vitamin K
deficiency in newborns. The present Dutch guideline
recommends 1 mg of vitamin K1 orally at birth, followed
by a daily dose of 25 μg of vitamin K1 from 1 to 13 weeks
of age for breastfed infants. Since the introduction of this
prophylaxis, the incidence of vitamin K deficiency bleeding
(VKDB) has decreased; however, late VKDB is still
reported. From 1 January to 31 December 2005, a
nationwide active surveillance was performed by the
Netherlands Paediatric Surveillance Unit (NSCK) to study
the current incidence and aetiology of late VKDB in
infants. Six cases could be validated as late VKDB: all
were breastfed, one fatal idiopathic intracranial haemor-
rhage at the age of 5 weeks and five bleedings secondary to
an underlying cholestatic liver disease between the age of 3
and 7 weeks. The total incidence of late VKDB and
idiopathic late VKDB was calculated to be 3.2 (95% CI:
1.2–6.9) and 0.5 (95% CI: 0–2.9) per 100,000 live births,
respectively. With the current Dutch guideline, idiopathic
late VKDB is rare but late VKDB secondary to cholestasis
still occurs in breastfed infants. Doubling the daily dose of
vitamin K1 to 50 μg, as is comparable to formula-feeding,
may possibly prevent VKDB in this group. Further
research, however, is needed to prove this hypothesis.
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Introduction
Vitamin K deficiency can cause severe haemorrhage in the
newborn. The term “haemorrhagic disease of the newborn”
(HDN) was coined by Charles Townsend in 1894 to
describe an acquired bleeding disorder in the newborn due
to vitamin K deficiency [26]. Nowadays, the term HDN is
replaced by vitamin K deficiency bleeding (VKDB), as
neonatalbleedingisoftennotduetovitaminKdeficiencyand
VKDB often occurs after the 4-week neonatal period [23].
VKDB can be classified according to the time of
presentation after birth into early (0–24 h), classical (1–
7 days) and late (2–12 weeks) VKDB. Late VKDB occurs
primarily in exclusively breastfed infants who have re-
ceived no or inadequate vitamin K prophylaxis. In addition,
intestinal malabsorption defects (cholestatic jaundice, cystic
fibrosis, α-1-antitrypsin deficiency etc.) are a well known
frequent cause of late VKDB [13]. In some children,
“warning bleeds” such as mild bruises, nose bleeds or
umbilical oozing are the first manifestation of VKDB. In
about 50% of the cases in late VKDB, intracranial
haemorrhage occurs, accounting for death and serious
neurological and mental handicaps [22]. The efficacy of
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prevention of classic VKDB is firmly established [16]. It
has been the standard of care since the Committee on
Nutrition of the American Academy of Paediatrics recom-
mended to administer vitamin K prophylaxis to all newborn
infants in 1961 [1]. Since then, many countries adopted this
recommendation, although controversies concerning the
best dose, route and frequency of administration still exist.
In 1990, the Dutch Paediatric Association recommended
the administration of a single oral dose of 1 mg of vitamin
K1 at birth to all healthy infants. Parenteral administration
of vitamin K1 at birth was recommended for newborns
especially at risk (preterm babies, babies born with
instrumental help or caesarean section, asphyxia or if
maternal medication was interfering with coagulation). For
infants who are largely or fully breastfed, a daily dose of
25 μg of vitamin K1 orally was recommended from 1 to
13 weeks of age. In case of additional risk factors like a
known malabsorption, this dose should be increased to
50 μg per day [29].
After the introduction of this guideline, the incidence of
late VKDB, which was studied by a nationwide active
surveillance performed by the Netherlands Paediatric
Surveillance Unit (NSCK) in 1992 to 1994, decreased from
about 7.0 to 1.1/100,000 live births [2]. However, still,
some cases of late VKDB have been reported in the
Netherlands, merely due to an underlying cholestatic liver
disease [7, 10, 11].
Therefore, a one-year surveillance was started again to
study the current incidence and the aetiology of late VKDB
in the Netherlands. Discussion will rise about the efficacy
of the current guideline in order to completely prevent late
VKDB.
Methods
From 1 January to 31 December 2005, an active surveil-
lance programme for VKDB was in operation in the
Netherlands, using methods developed by the British
Paediatric Association Surveillance Unit [8]. Surveillance
was based on monthly report cards sent to paediatricians
responsible for in- and outpatient care in all hospitals by the
NSCK. A “nothing to report” option was included. The
return rate of these report cards was 94.7% in 2004 [17].
The paediatricians were asked to report all infants in
whom bleeding may have resulted from VKDB. The
reported cases were validated with a questionnaire asking
for information about the infant, type of feeding, clinical
presentation, doseof vitaminKprophylaxis, route ofvitamin
K prophylaxis, associated diseases and laboratory data. For
all reported cases, we asked for an anonymous hospital
discharge letter to verify the diagnosis of late-onset VKDB.
The case definition of late-onset VKDB was as interna-
tionally defined: any infant between 8 days to 26 weeks of
age, with spontaneous bruising, bleeding or intracranial
haemorrhage associated with a grossly prolonged prothrom-
bin assay, not due to an inherited coagulopathy or
disseminated intravascular coagulation [23].
Confirmed VKDB was diagnosed when the prothrombin
assay results were grossly abnormal compared with the
standards for age: international normalized ratio (INR) ≥4
control value, prothrombin time (PT) ≥4 control value and
at least one of the following was present:
1. Platelet count normal or raised and normal fibrinogen
2. Prothrombin assay returned to normal after vitamin K
administration
3. Concentration of proteins induced by vitamin K
absence (PIVKA) exceeded normal controls
PIVKA is a sensitive indicator of vitamin K status,
allowing the detection of subclinical deficiency states
which would not be detected by conventional coagulation
assays [20].
Idiopathic cases were defined as cases in whom no factor
predisposing to vitamin K deficiency was identified.
Secondary cases were those in whom an underlying
condition such as cholestasis or other causes of malabsorp-
tion of vitamin K could be identified.
Vitamin K prophylaxis was considered to be “as
recommended” if the Dutch guideline was followed at the
time of bleeding: 1 mg of vitamin K1 (oral, intravenous,
intramuscular) directly after birth, followed by a daily dose
of 25 μg of vitamin K1 from 1 to 13 weeks of age for all
breastfed babies.
The Konakion mixed micellar preparate (Phytomenadion
10 mg/ml, Hoffmann-La Roche, Basel, Switzerland), which
can be used for both oral, intramuscular and intravenous
administration, an oral preparate called Davitamon K
(marketed by Chefaro, Rotterdam, the Netherlands, 25 μg/
5gtt) and an oral preparate, Phytomenadion, which is made
by the Dutch pharmacist Mixtura (Phytomenadion 10
mg/ml FNA) were the only vitamin K preparations licensed
in the Netherlands.
The 95% confidence intervals (CI) were calculated
according to a binomial distribution and the chi-squared
test was used for the comparison of incidences between
different periods, with a value of P<0.05 being considered
as significant.
Results
The response rate to the surveillance amounted to 93.4%
and the response to our questionnaires was 100%. In total,
seven cases of late VKDB were reported: four reports from
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hospitals. A hospital discharge letter was obtained in six
cases. In all cases, the diagnosis could be verified by the
completed questionnaire or the additional discharge letter.
One case did not fulfil the criteria of the case definition
because there were no clinical signs of bleeding, only
biochemical clotting disorders due to a vitamin K deficiency.
Six cases fulfilled the criteria of the case definition and
could be validated as late VKDB. The surveillance data are
shown in Table 1. The mean age of presentation was
5 weeks and 2 days, and all of the cases were exclusively
breastfed. In all cases, the PT time or INR was at least four
times greater than normal and vitamin K deficiency was
confirmed by a documented PT or INR normalisation after
the administration of vitamin K. Five of the cases also
received fresh frozen plasma.
Concerning the cause of VKDB, there was one case of
idiopathic VKDB, who presented with signs of bleeding at
the age of 5 weeks. She was breastfed and died due to the
consequence of an intracranial bleeding. She received
exactly the recommended prophylaxis. Unfortunately, no
post-mortem obduction was performed but, biochemically,
there were no signs of cholestasis. Five out of six cases
could be validated as secondary late VKDB. The age of
presentation in this group was between 3 and 7 weeks of
age. All of these bleedings were due to an underlying
cholestasis which was diagnosed after the first presentation
of bleeding. In two cases, an intracranial bleeding was the
first presenting sign. Four cases were diagnosed as having a
bile duct atresia. All infants had been exclusively breastfed
and all had received exactly the recommended prophylaxis.
In the study period, the number of live births amounted
to 187,910 [21]. Therefore, the total incidence of late
VKDB and idiopathic late VKDB was calculated to be 3.2
(95% CI: 1.2–6.9) and 0.5 (95% CI: 0–2.9) per 100,000
live births, respectively.
Discussion
Data from the United Kingdom, Germany and Switzerland
prove that intramuscular vitamin K1 prophylaxis (1 mg) is
highly effective in the prevention of late VKDB. This is
supported by data from Australia, which demonstrate a
higher incidence of late VKDB in babies who received oral
vitamin K compared to those with parenteral vitamin K at
birth. However, most of these failures of oral vitamin K
were in cases reported with an underlying cholestatic liver
disease [3, 12, 14, 25, 32, 33].
In 1992, Golding et al. [5] reported an increased risk of
developing childhood cancer after parenteral vitamin K1
prophylaxis. Recent studies, however, show that solid
tumours are no commoner in children who had parenteral
vitamin K. Although no convincing evidence between
parenteral vitamin K and childhood leukaemia was found
in these studies, it cannot be fully excluded that there is no
risk [4, 18].
Since the report of Golding et al., there has been an
increasing trend towards oral vitamin K administration and
many oral prophylaxis regimes have been developed.
In 1997, we summarised the results of surveillance
studies of over 2 million infants in four different countries
using different multiple oral dose schedules and parenteral
administration of vitamin K. A daily low oral dose of 25 μg
of vitamin K1 following an initial oral dose of 1 mg vitamin
K1 directly after birth for exclusively breastfed infants, as
was used in the Netherlands since 1990, seemed to be as
effective as parenteral vitamin K1 prophylaxis [3].
The present surveillance study shows that the current
Dutch guideline still seems quite effective in preventing
idiopathic late VKDB, but it is insufficient against
secondary late VKDB. In our surveillance, the incidence
of all late VKDB and idiopathic late VKDB was 3.2 (95%
CI: 1.2–6.9) and 0.5 (95% CI: 0–2.9) per 100,000 live
Table 1 Confirmed cases of late vitamin K deficiency bleeding (VKDB) in the Netherlands from 1 January to 31 December 2005
Patient; sex;
age (weeks)
Presentation Feeding Vitamin K prophylaxis Prothrombin assay
(after vitamin K administration)
Additional
morbidity
Outcome
of bleeding
A; female;
5+1/7
Intracranial
bleeding
Breastfeeding Birth: 1 mg
p.o.→25 μg/day
PT>120 s (13.3);
APTT>120 s (37)
No Died
B; female;
6+6/7
Intracranial
bleeding
Breastfeeding Birth: 1 mg
p.o.→25 μg/day
INR>8 (INR<2);
APTT>240 s (49)
Biliary
atresia
Hemipareses
right
C; male;
4+4/7
Intracranial
bleeding
Breastfeeding Birth: 1 mg
p.o.→25 μg/day
PT>90 s (30);
APTT>120 s (38);
Vitamin K: 0.1 nmol/l
Biliary
atresia
Hemipareses
right
D; male;
5+2/7
Nasal
bleeding
Breastfeeding Birth: 1 mg
p.o.→25 μg/day
PT>75 s (normal);
APTT: 118 s (normal)
Biliary
atresia
No sequelae
E; male;
6+2/7
Nasal
bleeding
Breastfeeding Birth: 1 mg
p.o.→25 μg/day
PT>165 s (normal);
APTT>240 s (normal)
Biliary
atresia
No sequelae
F; male;
3+6/7
Nasal
bleeding
Breastfeeding Birth: 1 mg
p.o.→25 μg/day
PT>71 s (12.7);
APTT: 128 s (39.1)
Cholestasis No sequelae
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ble to 0.5 (95% CI: 0.1–1.6) per 100,000 live births
reported in our surveillance study performed by the same
Netherlands Paediatric Surveillance Unit (NSCK) in 1992–
1994 [2]. The incidence of late VKDB secondary to an
underlying cholestatic liver disease is, however, significant-
ly higher (P<0.05); 2.7 (95% CI: 0.9–6.2) compared to 0.7
(95% CI: 0.1–2.0) in 1992–1994. A higher incidence of
cholestatic liver diseases in general or a delayed recognition
of symptoms can be explanations for this difference.
Unfortunately, data about the incidence or recognition of
cholestatic liver diseases in the Netherlands are not
available.
In this surveillance, there were no reports of late VKDB
after parenteral administration of vitamin K1. This can be
explained by the assumption of the higher efficacy of
parenteral vitamin K1 or the low use of intramuscular and
intravenous vitamin K1 these days.
Since 1994, a new preparate, Konakion mixed micellar,
has been available. This mixed micellar formulation is
prepared with the phospholipids lecithin and the bile salt
glycocholic acid, and it was presumed that this preparate
would reduce the incidence of late VKDB due to a better
absorption of oral vitamin K. However, a recent randomised
controlled trial shows that the mixed micellar vitamin K
gives unreliable and still severely impaired intestinal
absorption in infants with cholestasis [15]. Furthermore,
von Kries et al. [31] reported no significant reduction in the
incidence of late VKDB in healthy infants and infants with
an underlying cholestatic liver disease with this preparate
compared to the use of the original Konakion (Cremophor
EL) and Kanavit (Polysorbat 80).
In view of the fact that vitamin K has limited tissue
reserves and is rapidly catabolised, with 60–70% of a single
dose being excreted via the urine and bile in about 3 days, it
seems reasonable that repeated doses rather than a higher
single dose is more effective in preventing late VKDB [15].
An important study from Denmark has established that
1 mg of oral vitamin K1 given weekly during the first 3
months of life, following an initial oral dose of 2 mg of
vitamin K1 directly after birth, is as effective as 1 mg of
vitamin K1 given intramuscularly at birth [9]. Therefore, we
hypothesise that the dosage of 25 μg of vitamin K1 daily is
not enough to prevent the secondary cases of late VKDB,
as we encountered in this study.
In most co-operative studies, the upper age limit for
inclusion was set arbitrarily at the end of 12 weeks of age
[32]. In our study, we included infants presenting with
VKDB up to the age of 26 weeks of age, as suggested by
Tripp et al. [27]. However, no infant between 12 and
26 weeks of age was reported.
The mean age of all infants with late VKDB was
5 weeks, which is comparable to other reports [22].
In our study, the boy:girl ratio was 2.5:1. Why late
VKDB occurs more in boys than girls is unknown, but this
is consistent with other European reports [22, 24].
Unfortunately, this study has some limitations. First, this
surveillance was based on one data source only: the
Netherlands Paediatric Surveillance Unit. In spite of the
high return rate of the report cards (93.4%), it is plausible
that dramatic conditions, such as intracranial bleedings, are
more likely to be reported, as also noted by von Kries et al.
[31]. For this reason, our data could give an under-reporting
of the true incidence of late VKDB in the Netherlands.
However, the fact that 50% of late VKDB cases were
intracranial bleedings is comparable to other, larger reports
[3, 13, 14, 19, 22, 30, 31, 33].
Secondly, the surveillance lasted only 1 year. In all
probability, the confidence interval would be smaller when
the length of the surveillance was prolonged. Third, the
proportion of infants that is breastfed is unknown, and,
additionally, we lack data about compliance to the prophy-
laxis. It is likely, however, that less than 100% of the eligible
cases received the recommended prophylaxis. Prophylaxis
failure, therefore, is likely to be underestimated due to a
greater denominator than the true numbers exposed.
We would suggest to double the daily dose of vitamin K1
to 50 μg for all breastfed babies from 1 to 13 weeks of age
to prevent bleedings in infants with an underlying chole-
static liver disease as well. This amount is comparable to
the ingested dose of vitamin K1 by formula-feeding [6].
Formula is supplemented with vitamin K1 to a minimal
concentration of 50 μg/l. VKDB are not reported in
formula-fed babies and there is no evidence that they are
at an increased risk of childhood cancer [28]. Studies with
such a concentration of vitamin K1 have never been
performed and further research is necessary to study the
efficacy of this prophylaxis in infants with underlying
cholestatic liver disease. Due to the low incidence of late
VKDB, it would be difficult to perform a randomised trial
of 25 μg versus 50 μg of vitamin K1 daily. Alternatively, a
new surveillance for 1 or 2 years after implementing 50 μg
of vitamin K1 as the prophylaxis could give an indication of
the efficacy of this dose.
Furthermore, an earlier recognition of symptoms associ-
ated with cholestatic liver disease and immediate investi-
gation and treatment of “warning bleeds” helps to prevent
the severe consequences of secondary late VKDB.
In conclusion, with the current guideline of vitamin K
prophylaxisintheNetherlands,idiopathiclateVKDBisrare,
but late VKDB secondary to an underlying cholestatic liver
disease still occurs. We suggest to double the daily main-
tenance dose of vitamin K1 to 50 μg per day for all breastfed
infants from 1 to 13 weeks of age in order to prevent
bleedings in children with an underlying cholestatic liver
disease as well. Further research, however, is recommended.
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